甲状腺髓样癌：靶向治疗及未来方向。
Medullary thyroid carcinoma: targeted therapies and future directions.
机构信息
Endocrine Surgery Research Laboratory, Department of Surgery, University of Wisconsin, H4/722 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792, USA.
出版信息
J Oncol. 2009;2009:183031. doi: 10.1155/2009/183031. Epub 2009 Dec 24.
Abstract
Medullary thyroid cancer (MTC) is a rare neuroendocrine neoplasm that accounts for approximately 5% of all thyroid malignancies. The natural history of MTC is characterized by early lymph node and distant metastases, making complete surgical cure often impossible. Conventional chemotherapy and external beam radiation have been largely ineffective in altering the natural history of MTC. Therefore, there is a great need to develop novel therapeutic strategies to affect symptom control and reduce tumor burden in patients with widely disseminated disease. Here, we review several pathways which have been shown to be vital in MTC tumorigenesis and focus on the pathways of interest for which targeted drug therapies are currently being developed.
摘要
甲状腺髓样癌（MTC）是一种罕见的神经内分泌肿瘤，约占所有甲状腺恶性肿瘤的 5%。MTC 的自然病程以早期淋巴结和远处转移为特征，因此通常无法完全手术治愈。传统的化疗和外照射在改变 MTC 的自然病程方面效果甚微。因此，迫切需要开发新的治疗策略，以控制症状并减轻广泛播散性疾病患者的肿瘤负担。在这里，我们回顾了一些已被证明对 MTC 肿瘤发生至关重要的途径，并重点介绍了目前正在开发针对这些途径的靶向药物治疗的途径。
相似文献
1
Medullary thyroid carcinoma: targeted therapies and future directions.甲状腺髓样癌：靶向治疗及未来方向。
J Oncol. 2009;2009:183031. doi: 10.1155/2009/183031. Epub 2009 Dec 24.
2
Medullary thyroid carcinoma: management of lymph node metastases.甲状腺髓样癌：淋巴结转移的治疗。
J Natl Compr Canc Netw. 2010 May;8(5):549-56. doi: 10.6004/jnccn.2010.0042.
3
Breach of the thyroid capsule and lymph node capsule in node-positive papillary and medullary thyroid cancer: Different biology.甲状腺乳头状癌和髓样癌伴淋巴结转移时甲状腺被膜和淋巴结被膜侵犯：不同的生物学特性
Eur J Surg Oncol. 2015 Jun;41(6):766-72. doi: 10.1016/j.ejso.2014.10.049. Epub 2014 Oct 27.
4
Surgical strategy for the treatment of sporadic medullary thyroid carcinoma: our experience.散发性甲状腺髓样癌的手术治疗策略：我们的经验
G Chir. 2012 Nov-Dec;33(11-12):395-9.
5
Long-Term Follow-up in Medullary Thyroid Carcinoma.甲状腺髓样癌的长期随访
Recent Results Cancer Res. 2015;204:207-25. doi: 10.1007/978-3-319-22542-5_10.
6
Static Prognostic Factors and Appropriate Surgical Designs for Patients with Medullary Thyroid Carcinoma: The Second Report from a Single-Institution Study in Japan.甲状腺髓样癌患者的静态预后因素及合适的手术设计：来自日本单机构研究的第二次报告
World J Surg. 2018 Dec;42(12):3954-3966. doi: 10.1007/s00268-018-4738-z.
7
Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer.散发性和遗传性甲状腺髓样癌中央区及双侧淋巴结清扫的理论依据
J Clin Endocrinol Metab. 2003 May;88(5):2070-5. doi: 10.1210/jc.2002-021713.
8
Histone Deacetylase Inhibitors: A Novel Therapeutic Weapon Against Medullary Thyroid Cancer?组蛋白去乙酰化酶抑制剂：对抗甲状腺髓样癌的新型治疗武器？
Anticancer Res. 2016 Oct;36(10):5019-5024. doi: 10.21873/anticanres.11070.
9
Medullary Thyroid Cancer - Feature Review and Update on Systemic Treatment.甲状腺髓样癌——特征综述及系统治疗更新。
Acta Clin Croat. 2020 Jun;59(Suppl 1):50-59. doi: 10.20471/acc.2020.59.s1.06.
10
Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.甲状腺癌的管理：英国国家多学科指南
J Laryngol Otol. 2016 May;130(S2):S150-S160. doi: 10.1017/S0022215116000578.
引用本文的文献
1
A novel CCK2/gastrin receptor-localizing radiolabeled peptide probe for personalized diagnosis and therapy of patients with progressive or metastatic medullary thyroid carcinoma: a multicenter phase I GRAN-T-MTC study.一种用于进行性或转移性甲状腺髓样癌患者个性化诊断和治疗的新型CCK2/胃泌素受体定位放射性标记肽探针：一项多中心I期GRAN-T-MTC研究。
Pol Arch Intern Med. 2018 Dec 21;128(12):791-795. doi: 10.20452/pamw.4387. Epub 2018 Dec 5.
2
Thailandepsin A-loaded and octreotide-functionalized unimolecular micelles for targeted neuroendocrine cancer therapy.负载泰国胃蛋白酶A并功能化奥曲肽的单分子胶束用于靶向神经内分泌癌治疗
Biomaterials. 2016 Jun;91:1-10. doi: 10.1016/j.biomaterials.2016.03.010. Epub 2016 Mar 8.
3
Growth arrest signaling of the Raf/MEK/ERK pathway in cancer.癌症中Raf/MEK/ERK信号通路的生长阻滞信号
Front Biol (Beijing). 2014 Feb;9(2):95-103. doi: 10.1007/s11515-014-1299-x.
4
Cabozantinib for progressive metastatic medullary thyroid cancer: a review.卡博替尼用于进展性转移性甲状腺髓样癌：一项综述
Ther Clin Risk Manag. 2014 May 28;10:395-404. doi: 10.2147/TCRM.S46041. eCollection 2014.
5
The Role of STAT3 in Thyroid Cancer.STAT3 在甲状腺癌中的作用。
Cancers (Basel). 2014 Mar 6;6(1):526-44. doi: 10.3390/cancers6010526.
6
New developments in the diagnosis and treatment of thyroid cancer.甲状腺癌的诊断与治疗新进展。
CA Cancer J Clin. 2013 Nov-Dec;63(6):374-94. doi: 10.3322/caac.21195. Epub 2013 Jun 24.
7
Glucagon-Like Peptide-1 Receptor Imaging with [Lys (40) (Ahx-HYNIC- (99 m) Tc/EDDA)NH 2 ]-Exendin-4 for the Diagnosis of Recurrence or Dissemination of Medullary Thyroid Cancer: A Preliminary Report.用 [Lys（40）（Ahx-HYNIC-（99m）Tc/EDDA）NH2]-Exendin-4 进行胰高血糖素样肽-1 受体成像诊断甲状腺髓样癌的复发或转移：初步报告。
Int J Endocrinol. 2013;2013:384508. doi: 10.1155/2013/384508. Epub 2013 Mar 31.
本文引用的文献
1
Regulation of cell-cell contact molecules and the metastatic phenotype of medullary thyroid carcinoma by the Raf-1/MEK/ERK pathway.Raf-1/MEK/ERK信号通路对甲状腺髓样癌细胞间接触分子及转移表型的调控
Surgery. 2008 Dec;144(6):920-4; discussion 924-5. doi: 10.1016/j.surg.2008.07.020.
2
Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.表达RET种系突变的甲状腺髓样癌的蛋白质组学研究：新信号元件的鉴定
Mol Carcinog. 2009 Mar;48(3):220-231. doi: 10.1002/mc.20474.
3
Motesanib diphosphate in progressive differentiated thyroid cancer.二磷酸莫替沙尼治疗进展性分化型甲状腺癌
N Engl J Med. 2008 Jul 3;359(1):31-42. doi: 10.1056/NEJMoa075853.
4
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.阿昔替尼对晚期甲状腺癌的所有组织学亚型均为有效的治疗方法：一项II期研究的结果
J Clin Oncol. 2008 Oct 10;26(29):4708-13. doi: 10.1200/JCO.2007.15.9566. Epub 2008 Jun 9.
5
Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells.丙戊酸激活Notch1信号通路并诱导甲状腺髓样癌细胞凋亡。
Ann Surg. 2008 Jun;247(6):1036-40. doi: 10.1097/SLA.0b013e3181758d0e.
6
Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors.胃肠道神经内分泌肿瘤治疗与缓解的新靶点。
Curr Opin Investig Drugs. 2008 Jun;9(6):576-82.
7
Current management of medullary thyroid cancer.甲状腺髓样癌的当前管理
Oncologist. 2008 May;13(5):539-47. doi: 10.1634/theoncologist.2007-0239.
8
Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells.辛二酰双羟肟酸激活Notch-1信号通路并诱导甲状腺髓样癌细胞凋亡。
Oncologist. 2008 Feb;13(2):98-104. doi: 10.1634/theoncologist.2007-0190.
9
Neuroendocrine tumor cell growth inhibition by ZM336372 through alterations in multiple signaling pathways.ZM336372通过多种信号通路的改变抑制神经内分泌肿瘤细胞生长。
Surgery. 2007 Dec;142(6):959-64; discussion 959-64. doi: 10.1016/j.surg.2007.09.020.
10
Fine-needle aspiration may miss a third of all malignancy in palpable thyroid nodules: a comprehensive literature review.细针穿刺可能会漏诊三分之一可触及的甲状腺结节中的所有恶性肿瘤：一项全面的文献综述。
Ann Surg. 2007 Nov;246(5):714-20. doi: 10.1097/SLA.0b013e3180f61adc.
Zotero 插件